Citations

Clear

912 citation(s) found for "Yu, Caroline".

Effect on Kidney Function During Gender Affirming Hormonal Treatment in Transgender Individuals
Maheshwari, Arvind , Dines, Virginia , Davidge‐Pitts, Caroline , Kattah, Andrea G.

Mayo Clinic

Journal of the Endocrine Society | May 3, 2021 | Volume: 5 | Issue: Supplement_1 | Pages: A790-A790

10.1210/jendso/bvab048.1607 Get It

Abstract Background: Accurate interpretation of laboratory values with sex-specific reference ranges presents a challenge in transgender individuals on gender affirming hormone therapy (GAHT). Creatinine (Cr), the most common marker used for kidney function, varies significantly with body mass and composition. Both Modification of Diet in Renal Disease (MDRD) and Chronic Kidney Disease Epidemiology Collaboration (CKD-Epi) equations account for sex in estimating glomerular filtration rate. GAHT can effect Cr values in 2 potential ways: 1) by causing changes in muscle mass and body fat redistribution as early as 3 months after GAHT initiation and 2) by direct effects of sex hormones on kidney function. Previous studies have shown Cr values approaching affirmed gender identity as early as 6 months when on GAHT without mention of sex steroid levels. In this study we sought to describe the changes in serum Cr after initiation of GAHT in an effort to better understand expected changes and interpretation of lab data in TG individuals. Methods: A retrospective chart analysis on all adult TG patients initiated on GAHT at our institution from January 2011 to 2020 was completed. We reviewed demographics, baseline health information, body mass index, and lab values including Cr, sex hormone levels, A1C, and fasting blood glucose. Lab values were obtained prior to GAHT, at the start of GAHT, at 3, 6, and 12 months after GAHT. Matched pair testing was conducted with sex steroid levels and Cr values in transgender men (TM) on testosterone and transgender women (TW) on estradiol in order to compare the median pre GAHT Cr to median Cr levels at 3, 6, and 12 months. Results: 84 TW with a median age of 30 and 24 TM with a median age of 23 were included for analysis. TW and TM had a low rate of existing kidney disease (4.9%, 0%), diabetes mellitus (4.8%, 0%), and hypertension (10.8%, 4.5%) respectively. TW on GAHT achieved a goal estradiol level (≥100 pg/ml) at a rate of 37.3%, 51.7%, and 71.1% and suppressed testosterone to a goal level (<60ng/ml) at a rate of 44.4%, 54.7%, and 76.5% at 3, 6, and 12 months respectively. There was no significant change in Cr values at 3 months, but significantly decreased on average by -0.07 (p<0.001) at 6 months, and by -0.09 (p<0.001) at 12 months. TM on GAHT achieved a goal testosterone level (≥240 ng/dl) at a rate of 64.3%, 80.0%, and 72.3% at 3, 6, and 12 months respectively. Cr values increased significantly on average by 0.14 (p=0.036) at 3 months, by 0.21 (p=0.004) at 6 months, and by 0.15 (p=0.003) at 12 months. Conclusions: In TW on GAHT, clinicians can consider using affirmed gender Cr reference ranges as early as 6 months. Similarly in TM on GAHT, affirmed gender Cr reference ranges can be used as early at 3 months. It remains to be seen whether changes in Cr levels reflect changes in sex steroid levels or sex steroid direct effects. Additionally, research is needed to determine if change in Cr levels reflect true changes in GFR.
Characterization of Thyroid Disease Prevalence Among Transgender and Gender-Diverse Patients
Christensen, John D. , Davidge‐Pitts, Caroline , Castro, M. Regina , Caraballo, Pedro J.

Mayo Clinic

Journal of the Endocrine Society | May 3, 2021 | Volume: 5 | Issue: Supplement_1 | Pages: A837-A838

10.1210/jendso/bvab048.1709 Get It

Abstract Objective: Transgender and gender-diverse individuals are at risk of insufficient treatment of endocrine diseases due to a number of barriers to care. There are currently no data evaluating the prevalence of thyroid disease in this population, and it is unknown if gender-affirming hormone therapy affects treatment of thyroid disease in these individuals. Methods: Utilizing a registry of 676 patients over 18 years of age who were seen in our Transgender and Intersex Specialty Care Clinic from 2015-2019, we identified 554 individuals seeking medical therapy for gender dysphoria/incongruence. Of these, 56 patients were taking thyroid hormone or antithyroid medications or had a coded diagnosis of thyroid disease; 2 were excluded as they were receiving thyroid hormone as adjunctive therapy for refractory depression. 54 patients were therefore analyzed with respect to thyroid disease (TD+), and compared to those 498 patients without thyroid disease (TD-) with regard to average vital signs, demographics, and presence of common comorbidities. Results: Fifty percent of our TD+ patients were recorded female sex at birth, and 98% were Caucasian. TD+ patients were much more likely to have essential hypertension (OR 5.99), to use tobacco (OR 2.23), and to be overweight or obese (OR 2.16) than TD- patients. Due to the evolving natural history of disease, some TD+ patients belonged to multiple categories: 48 patients, 26 trans feminine and 21 trans masculine, had hypothyroidism, of whom 41 had overt hypothyroidism and 2 patients had subacute thyroiditis that progressed to the hypothyroid phase of illness. 5 patients (3 trans masculine and 2 trans feminine) demonstrated hyperthyroidism, 4 of whom had Graves’ Disease. 2 patients had multinodular goiter, both trans masculine. 2 patients had thyroid malignancies, both trans feminine, of whom one had proven follicular thyroid carcinoma and the other had unspecified thyroid malignancy. Among hypothyroid patients, there was a slight non-significant trend toward increased thyroid hormone requirements while receiving treatment with estradiol or testosterone. Conclusion: To our knowledge, this represents the first attempt to characterize the prevalence of various thyroid disease states in the gender diverse population. Our data corresponded to a prevalence of hypothyroidism of approximately 8.7%, which is higher than previously published estimates of 3-5% in the general population. Whether this represents actual increased prevalence or assessment bias is uncertain. It is important for all health professionals who care for gender diverse people to identify and appropriately treat thyroid disease, and to monitor thyroid function closely if gender-affirming hormone therapy is initiated.
Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease
Lai, Dongbing , Fontanillas, Pierre , Aasly, Jan , Beecham, Gary W. , Berg, Daniela , Bressman, Susan , Brockmann, Kathrin , Clark, Lorraine N. , Cookson, Mark , Das, Sayantan , Farrer, Matthew J. , Trinh, Joanne , Gasser, Thomas , Gustavsson, Emil K. , Klein, Christine , Langston, J. William, Lynch, Timothy , Marder, Karen, Martin, Eden R. , Mejia‐Santana, Helen, Molho, Eric , Nuytemans, Karen , Ozelius, Laurie J. , Raymond, Deborah , Ross, Owen A. , Samii, Ali, Saunders‐Pullman, Rachel , Schüle, Birgitt , Tolosa, Eduardo , Tomkins, James E. , Vilas, Dolores , Trojanowski, John Q. , Uitti, Ryan J. , Zabetian, Cyrus P. , Urtreger, Avi Orr, Cannon, P. F. , Fiske, Brian , Brockman, Kathrin , Klein, Christine , Ross, Owen A , Uitti, Ryan, Visanji, Naomi P , Zabetian, Cyrus P , Mirelman, Anat , Alipanahi, Babak , Schwantes-An, Tae-Hwi Linus , Alcalay, Roy N. , Brice, Alexis , Deerlin, Vivianna M. Van , Follett, Jordan , Goldwurm, Stefano , Lang, Anthony E. , Latourelle, Jeanne C. , Marras, Connie , McLean, Cory Y. , Myers, Richard H. , Payami, Haydeh , Rogaeva, Ekaterina A. , Rogers, Michael P. , Schulte, Claudia , Scott, William K. , Tanner, Caroline M. , Vance, Jeffery M. , Visanji, Naomi P. , Wszołek, Zbigniew K. , Giladi, Nir , Foroud, Tatiana

Mayo Clinic

Annals of Neurology | May 3, 2021 | Volume: 90 | Issue: 1 | Pages: 76-88

10.1002/ana.26094 | PMID 33938021 Get It

Objective The aim of this study was to search for genes/variants that modify the effect of LRRK2 mutations in terms of penetrance and age‐at‐onset of Parkinson's disease. Methods We performed the first genomewide association study of penetrance and age‐at‐onset of Parkinson's disease in LRRK2 mutation carriers (776 cases and 1,103 non‐cases at their last evaluation). Cox proportional hazard models and linear mixed models were used to identify modifiers of penetrance and age‐at‐onset of LRRK2 mutations, respectively. We also investigated whether a polygenic risk score derived from a published genomewide association study of Parkinson's disease was able to explain variability in penetrance and age‐at‐onset in LRRK2 mutation carriers. Results A variant located in the intronic region of CORO1C on chromosome 12 (rs77395454; p value = 2.5E‐08, beta = 1.27, SE = 0.23, risk allele: C) met genomewide significance for the penetrance model. Co‐immunoprecipitation analyses of LRRK2 and CORO1C supported an interaction between these 2 proteins. A region on chromosome 3, within a previously reported linkage peak for Parkinson's disease susceptibility, showed suggestive associations in both models (penetrance top variant: p value = 1.1E‐07; age‐at‐onset top variant: p value = 9.3E‐07). A polygenic risk score derived from publicly available Parkinson's disease summary statistics was a significant predictor of penetrance, but not of age‐at‐onset. Interpretation This study suggests that variants within or near CORO1C may modify the penetrance of LRRK2 mutations. In addition, common Parkinson's disease associated variants collectively increase the penetrance of LRRK2 mutations. ANN NEUROL 2021;90:82–94
An Approach to Nonsuppressed Testosterone in Transgender Women Receiving Gender-Affirming Feminizing Hormonal Therapy
Maheshwari, Arvind , Nippoldt, Todd B., Davidge‐Pitts, Caroline , Nippoldt, Todd

Mayo Clinic

Journal of the Endocrine Society | April 17, 2021 | Volume: 5 | Issue: 9 | Pages: No page available

10.1210/jendso/bvab068 | PMID 34278180 Get It

AbstractNonsuppressed levels of testosterone are seen in up to a quarter of transgender women on gender-affirming feminizing hormonal treatment. Multiple factors contribute to this situation, including patient, medication, laboratory, and organ-specific concerns. We propose a stepwise approach to determine the etiology of nonsuppressed levels of testosterone in transgender women. This may lead to an appropriate feminizing hormonal therapy regimen and diagnosis of manageable medical conditions.
Magnetic resonance biomarkers in radiation oncology: The report of AAPM Task Group 294
McGee, Kiaran P. , Hwang, Ken‐Pin, Sullivan, Daniel C. , Hu, Yanle , Debbins, Josef P., Paulson, E.S. , Olsen, Jeffrey R., Hua, Chia‐Ho , Warner, Lizette, Tyagi, Neelam , Chung, Caroline , Kurhanewicz, John V. , Wang, Jihong , Li, Wen , Daniel, J. , Moros, Eduardo G.

Mayo Clinic

Medical Physics | April 17, 2021 | Volume: 48 | Issue: 7 | Pages: No page available

10.1002/mp.14884 | PMID 33864283 Get It

PurposeA magnetic resonance (MR) biologic marker (biomarker) is a measurable quantitative characteristic that is an indicator of normal biological and pathogenetic processes or a response to therapeutic intervention derived from the MR imaging process. There is significant potential for MR biomarkers to facilitate personalized approaches to cancer care through more precise disease targeting by quantifying normal versus pathologic tissue function as well as toxicity to both radiation and chemotherapy. Both of which have the potential to increase the therapeutic ratio and provide earlier, more accurate monitoring of treatment response. The ongoing integration of MR into routine clinical radiation therapy (RT) planning and the development of MR guided radiation therapy systems is providing new opportunities for MR biomarkers to personalize and improve clinical outcomes. Their appropriate use, however, must be based on knowledge of the physical origin of the biomarker signal, the relationship to the underlying biological processes, and their strengths and limitations. The purpose of this report is to provide an educational resource describing MR biomarkers, the techniques used to quantify them, their strengths and weakness within the context of their application to radiation oncology so as to ensure their appropriate use and application within this field.
A Taxonomic Review of Patient Complaints in Adult Hospital Medicine
Eliáš, Richard , Siddiqui, Mustaqeem , Coons, Trevor J. , Meyerhofer, Cindy A, Pretzman, Holly J, Greig, Hope E, Stevens, Sheila K., Burton, M. Caroline , Elias, Richard M , Siddiqui, Mustaqeem A , Coons, Trevor , Fischer, Karen M.

Mayo Clinic

Journal of Patient Experience | April 9, 2021 | Volume: 8 | Issue: No issue available | Pages: No page available

10.1177/23743735211007351 | PMID 34179414 Get It

Previous studies show that patient complaints can identify gaps in quality of care, but it is difficult to identify trends without categorization. We conducted a review of complaints relating to admissions on hospital internal medicine (HIM) services over a 26-month period. Data were collected on person characteristics and key features of the complaint. The complaints were also categorized into a previously published taxonomy. Seventy-six unsolicited complaints were identified, (3.5 per 1000 hospital admissions). Complaints were more likely on resident services. The mean duration between encounter and complaint was 18 days, and it took an average of 12 days to resolve the complaint. Most patients (59%) had a complaint in the Relationship domain. Thirty-nine percent of complaints mentioned a specific clinician. When a clinician was mentioned, complaints regarding communication and humaneness predominated (68%). The results indicate that the efforts to reduce patient complaints in HIM should focus on the Relationships domain.
Hospitalist perspectives on barriers to recommend and potential benefit of the COVID-19 vaccine
Dugani, Sagar B. , Geyer, Holly L. , Maniaci, Michael J. , Fischer, Karen M. , Croghan, Ivana T. , Coons, Trevor J. , Canan, Elizabeth L. , Burton, M. Caroline , Fischer, Karen M , Coons, Trevor , Maniaci, Michael J , Dugani, Sagar B

Mayo Clinic

Hospital Practice | April 7, 2021 | Volume: 49 | Issue: 4 | Pages: 245-251

10.1080/21548331.2021.1914465 | PMID 33826433 Get It

Crossing the Carotid Siphon: Techniques to Facilitate Distal Access in Tortuous Anatomy: 2-Dimensional Operative Video
Hadley, Caroline , Burkhardt, Jan‐Karl , Johnson, Jeremiah N., Kan, Peter , Bain, Mark, Bendock, Bernard, Binning, Mandy J., Boulos, Alan S. , Crowley, Webster, Fessler, Richard D., Guterman, Lee R., Hoit, Daniel , Hopkins, L. Nelson , Howington, Jay U., James, Robert F. , Jankowitz, Brian T. , Khalessi, Alex A, Kim, Louis J. , Langer, David J. , Levitt, Michael R. , Mack, William J. , Mericle, Robert A., Ogilvy, Chris, Replogle, Robert, Riina, Howard A. , Saugaveau, Eric, Schirmer, Clemens M. , Spiotta, Alex, Sultan, Ali, Turner, Raymond D , Veznedaroglu, Erol, Welch, Babu G. , White, Jonathan, Ogilvy, Christopher S. , Levitt, Michael R , Burkhardt, Jan-Karl , Schirmer, Clemens M , Ogilvy, Christopher S , Burkhardt, Jan‐Karl , Arthur, Adam Stephen , Grande, Andrew Walker , Hanel, Ricardó A. , Kim, Louis J. , Lanzino, Giuseppe , Levy, Elad I. , Lopes, Demetrius K. , Mocco, J , Pandey, Aditya S , Ringer, Andrew J. , Rodriguez, Rafael, Siddiqui, Adnan H. , Tawk, Rabih G. , Thomas, Ajith J , White, Jonathan A.

Mayo Clinic

Operative Neurosurgery | April 6, 2021 | Volume: 21 | Issue: 1 | Pages: E41-E42

10.1093/ons/opab084 | PMID 33822191 Get It

Abstract As capabilities for endovascular treatment of intracranial vascular pathologies continue to expand, the need for access to the distal internal carotid artery with rigid support catheter systems continues to increase. One of the dominant factors limiting this access is patient anatomy, specifically vessel tortuosity. Increased tortuosity of the carotid siphon is a frequently encountered anatomic variant and may complicate endovascular procedures in adults and children. 1,2 Failed attempts to navigate the carotid siphon with a distal access catheter carry a risk of vessel injury and treatment failure. For this reason, techniques that aid in supporting safe advancement of a distal access catheter across a tortuous carotid siphon are essential. 3,4 In this video, we demonstrate 2 ways in which this may be accomplished. The first technique uses a larger diameter microcatheter, such as the AXS Offset catheter (Stryker, Kalamazoo, Michigan), to increase support for the distal access catheter, while the second uses a buddy wire technique to accomplish this increased support. Both of these techniques can help increase the safety of navigating a tortuous carotid siphon and increase the likelihood of successful treatment. The procedures shown were performed with the informed consent of the patients.
Clinical predictors of non‐response to lithium treatment in the Pharmacogenomics of Bipolar Disorder (PGBD) study
Lin, Yian , Maihofer, Adam X. , Stapp, Emma K. , Ritchey, Megan, Anand, Amit , Balaraman, Yokesh, Berrettini, Wade H. , Bertram, Holli , Bhattacharjee, Abesh Kumar, Calkin, Cynthia , Conroy, Carla , Coryell, William , D’Arcangelo, Nicole, DeModena, Anna, Fisher, Carrie, Frazier, Nicole, Frye, Mark A. , Gao, Keming , Glazer, Kara, Karberg, Elizabeth , Harrington, Gloria, Kamali, Masoud , Kelly, Marisa , Leckband, Susan G. , Lohoff, Falk W. , Stautland, Andrea , McCarthy, Michael J. , McInnis, Melvin G. , Mondimore, Francis M. , Øedegaard, Ketil J. , Syrstad, Vigdis Elin Giever, Ryan, Kelly A. , Schinagle, Martha , Schoeyen, Helle K., Shaw, Marth, Shilling, Paul D. , Slaney, Claire , Tarwater, Bruce, Calabrese, Joseph R. , Zandi, Peter P. , Anand, Amit , Coryell, William , Biernacka, Joanna , Frye, Mark, Gao, Keming , Nurnberger, John I , Alda, Martin , Zandi, Peter P , Kamali, Masoud , Calkin, Cynthia V , McCarthy, Michael , McInnis, Melvin G , Ritchey, Megan, Alliey‐Rodriguez, Ney , Biernacka, Joanna M. , Garnham, Julie , Gershon, Elliot S. , Goes, Fernando , Goto, Toyomi , Karberg, Elizabeth, Jakobsen, Petter , Morken, Gunnar , Syrstad, Vigdis Elin Giæver , Andreassen, Ole A. , Alda, Martin , Nievergelt, Caroline M , Kelsoe, John R

Mayo Clinic

Bipolar Disorders | April 2, 2021 | Volume: 23 | Issue: 8 | Pages: 821-831

10.1111/bdi.13078 | PMID 33797828 Get It

AbstractBackgroundLithium is regarded as a first‐line treatment for bipolar disorder (BD), but partial response and non‐response commonly occurs. There exists a need to identify lithium non‐responders prior to initiating treatment. The Pharmacogenomics of Bipolar Disorder (PGBD) Study was designed to identify predictors of lithium response.MethodsThe PGBD Study was an eleven site prospective trial of lithium treatment in bipolar I disorder. Subjects were stabilized on lithium monotherapy over 4 months and gradually discontinued from all other psychotropic medications. After ensuring a sustained clinical remission (defined by a score of ≤3 on the CGI for 4 weeks) had been achieved, subjects were followed for up to 2 years to monitor clinical response. Cox proportional hazard models were used to examine the relationship between clinical measures and time until failure to remit or relapse.ResultsA total of 345 individuals were enrolled into the study and included in the analysis. Of these, 101 subjects failed to remit or relapsed, 88 achieved remission and continued to study completion, and 156 were terminated from the study for other reasons. Significant clinical predictors of treatment failure (p < 0.05) included baseline anxiety symptoms, functional impairments, negative life events and lifetime clinical features such as a history of migraine, suicidal ideation/attempts, and mixed episodes, as well as a chronic course of illness.ConclusionsIn this PGBD Study of lithium response, several clinical features were found to be associated with failure to respond to lithium. Future validation is needed to confirm these clinical predictors of treatment failure and their use clinically to distinguish who will do well on lithium before starting pharmacotherapy.
Response to Letter to the Editor from Malone: “Proper Care of Transgender and Gender Diverse Persons in the Setting of Proposed Discrimination: A Policy Perspective”
Walch, Abby , Davidge‐Pitts, Caroline , Tangpricha, Vin , Iwamoto, Sean J. , Safer, Joshua D. , Tangpricha, Vin , Iwamoto, Sean J , Safer, Joshua D , López, Ximena

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | March 27, 2021 | Volume: 106 | Issue: 8 | Pages: e3295-e3296

10.1210/clinem/dgab206 | PMID 33772302 Get It